Analysis of a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Beijing of China.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
We report and analyze a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Chaoyang District of Beijing and to evaluate the causality between the disease and vaccination. Based on the professional branch of this case, we organized a seminar and we invited specialists in vaccinology, epidemiology, dermatology, infectiology, and immunology to participate in the conference. Specialists evaluated the relevance and causality between the vaccination and disease. The clinical diagnosis of the adolescent was pilomatricoma after receiving recombinant hepatitis B vaccine (CHO cell) which could not be disregarded as an adverse reaction following immunization. Although rare, there is a possibility of developing pilomatricoma after vaccination. This suggests that the implementation process of vaccination should be standardized and that the injection site after vaccination should be nursed properly.